CoronaryAtlas logo
CoronaryAtlas
ASCVD Risk Atlas
← Back to table
A

Total cholesterol

Lipids & LipoproteinsLab test / biomarkerriskmodifiable
60
evidence score

Also known as: cholesterol, cholesterol level, cholesterol levels, elevated total cholesterol, elevated total cholesterol (TC), hypercholesterolaemia, hypercholesterolemia, total cholesterol (TC), 188.0 mg/dL, total cholesterol (chol), total cholesterol concentration

PREVENT status

✓ Used by PREVENT (core input).

Also used by the Pooled Cohort Equations.

Causal support

trial evidence

Score components
lit volume: 25meta-analyses: 20trials: 15genetic: 0MR bonus:

References (317)

31 meta-analyses / systematic reviews

Clinical trials (365)

showing top 60
NCTTitleStatusTypeInterventions
NCT07626281A Randomized, Open-label, Single-dose, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Inclisiran Containing Polysorbate 80 Versus Inclisiran Alone in Participants With Elevated Low-density Lipoprotein CholesterolRECRUITINGINTERVENTIONALInclisiran formulation containing PS80, Currently marketed inclisiran formulation
NCT07428473A Phase 1 Open-Label Single Ascending Dose (Part 1) and Single or Multi-Dose Expansion (Part 2) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)RECRUITINGINTERVENTIONALSTX-1150
NCT07581808PCSK9-DUO Trial: Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Patients With High Cardiovascular Risk in Secondary PreventionRECRUITINGINTERVENTIONALInclisiran, Alirocumab
NCT07614958A Double-Blind, Randomized, Comparative Study of Obicetrapib and Bempedoic Acid on Top of Maximally Tolerated Lipid-Lowering Therapy in Patients With Dyslipidemia at High to Very High Cardiovascular RiskRECRUITINGINTERVENTIONALObicetrapib 10 mg/Bempedoic Acid Placebo, Bempedoic Acid 180mg/Placebo Obicetrapib
NCT07359105A Registry-based Randomized Controlled Trial of Moderate-intensity Statin Therapy vs. Individualized Low-density Lipoprotein Cholesterol Target-based Therapy for Primary Prevention of Cardiovascular Events in Patients 70 Years of Age or Older With Type 2 Diabetes (iTARGET-Elderly Study)RECRUITINGINTERVENTIONALModerate-intensity statin monotherapy, Ezetimibe or ezetimibe-statin combination therapy
NCT06988462Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" FoodRECRUITINGINTERVENTIONALBottarga, Comparator
NCT06960902Study of the Determinants of Coronary Atherosclerosis in Familial HypercholesterolemiaRECRUITINGINTERVENTIONALCoronary CT scan with CAC score measurement
NCT07058077An Operationally Seamless Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Enlicitide Decanoate in Pediatric Participants With Heterozygous Familial HypercholesterolemiaRECRUITINGINTERVENTIONALEnlicitide Decanoate, Placebo
NCT07478887Corrie Lipids Program: Optimizing LDL-Cholesterol by Improving Awareness, Access, and AchievementRECRUITINGINTERVENTIONALCorrie Lipids Digital Health Program
NCT06597006Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Children (2 to Less Than 12 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterolRECRUITINGINTERVENTIONALInclisiran, Placebo
NCT06501443Latin America Lipid Optimization After Acute Event in Patients With AthErosclerotic CardiovasculaR DiseaSe and High LDL-CRECRUITINGINTERVENTIONALUsual care, KJX839
NCT06597019Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children (6 to Less Than 12 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL- CholesterolRECRUITINGINTERVENTIONALInclisiran, Placebo
NCT06649240Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke (SVO70)RECRUITINGINTERVENTIONALStatins and/or Ezetimibe, PCSK9 inhibitor
NCT06535542A Randomized Trial of Integrating Whole Genome Sequencing and Digital Twins Into the Management of Hypercholesterolemia in EmiratisRECRUITINGINTERVENTIONALWhole Genome Sequencing
NCT06372925A Multi-Center, Randomized, Open-label, Parallel, Controlled Phase Ⅳ Clinical Trial to Evaluate the Effect of Inclisiran on Coronary Atherosclerotic Plaque in Patients With Acute Myocardial Infarction and Elevated Low-density Lipoprotein CholesterolRECRUITINGINTERVENTIONALatorvastatin, IVUS/OCT, inclisiran
NCT06526013Cholesterol Self-testing in Patients Post Acute Coronary SyndromeRECRUITINGINTERVENTIONALCholesterol self-measurement
NCT05614219Can Biochemistry Interpretive Comments on Elevated Cholesterol Levels, Increase Referrals to Lipid Clinics and Detection Rate of Familial Hypercholesterolemia? A Step Wedge Cluster Randomized Controlled Trial.RECRUITINGINTERVENTIONALBiochemistry interpretive comment on elevated LDL-C levels
NCT06125847A Clinical Study for the Safety and Efficacy of Intravenous Infusion of NGGT006 in Treatment of Homozygous Familial Hypercholesterolemia With LDLR MutationsRECRUITINGINTERVENTIONALNGGT006
NCT05765370LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With Atherosclerotic Cardiovascular Disease (TARGET OLD)RECRUITINGINTERVENTIONALAchieving a Target LDL-C level of 25mg/dL≤ LDL-C<70mg/dL, Achieving a Target LDL-C level of 70mg/dL≤ LDL-C<100mg/dL
NCT04073797PET Imaging of Inflammation and Lipid Lowering StudyRECRUITINGINTERVENTIONALInclisiran, 68Ga-DOTATATE PET-MRI, Colchicine
NCT03480568A Phase III Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen: The Alidial StudyRECRUITINGINTERVENTIONALAlirocumab 150 MG/ML [Praluent]
NCT07619131A Phase III Randomised, Double-Blind, Factorial Design Study to Assess the Effect of Fixed Dose Combination Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on Low-Density Lipoprotein Cholesterol in Lipid-Lowering Treatment-Naïve PatientsNOT YET RECRUITINGINTERVENTIONALLaroprovstat, Rosuvastatin 1, Rosuvastatin 2
NCT07515573A Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Parallel-Group Clinical Trial With an Open-Label Extension to Evaluate the Effects of a Combination Dietary Supplement (Cardiol Forte) on Lipid and Glycemic Parameters in Subjects at Low Cardiovascular Risk With Suboptimal Cholesterol LevelsNOT YET RECRUITINGINTERVENTIONALCardiol Forte, Placebo
NCT07441317A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of QLC7401 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia With Poorly Controlled Low-density Lipoprotein Cholesterol (LDL-C) Elevated on Optimized Lipid-lowering TherapyNOT YET RECRUITINGINTERVENTIONALQLC7401, Placebo
NCT07391722A Multicentre, Randomized, Double-Blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of DNV001 Injection at Different Dosages in Patients With Primary Hypercholesterolaemia or Mixed Hyperlipidaemia and Elevated Low Density Lipoprotein Cholesterol (LDL-C) InadequateNOT YET RECRUITINGINTERVENTIONALDNV001 Injection, Placebo
NCT07368608A Randomized, Double-blind, Placebo-controlled Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Subcutaneous BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated LDL-CNOT YET RECRUITINGINTERVENTIONALBEBT-701 Injection, BEBT-701 Injection Placebo（0.9% Sodium Chloride Injection）
NCT07290699INtensive Cholesterol-Lowering With recatIcimab combiNation in Emergency PCI for Acute Myocardial Infarction: A Randomized Controlled TrialNOT YET RECRUITINGINTERVENTIONALRecaticimab
NCT07170852Single Dose Oral Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets in Healthy Adult Human Subjects Under Fasting ConditionsCOMPLETEDINTERVENTIONALBempedoic acid film coated tablet, Nilemdo® Film-coated tablets
NCT06925100A Multicenter, Prospective, Phase IV, Interventional Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan - The CLEAR Taiwan StudyCOMPLETEDINTERVENTIONALBempedoic acid 180 mg tablet
NCT05988866Effects of a Digital Health Application (Lipodia) on LDL-cholesterol Levels in Individuals With LDL-cholesterol Levels Above Recommended Targets for Reducing Cardiovascular Risk: Randomized Controlled TrialCOMPLETEDINTERVENTIONALlipodia
NCT07421232A Phase Ⅱ Randomized, Parallel-group, Placebo-controlled, Active-controlled Trial to Assess the Efficacy, Safety of the SYH2053 Subcutaneous Injection in Participants With Primary Hypercholesterolemia or Mixed DyslipidemiaCOMPLETEDINTERVENTIONALSYH2053/placebo injection, Inclisiran (Leqvio®) 300mg
NCT06386419A Real-world, Prospective, Multi-center, Open-label, Phase 4 Clinical Study to Evaluate the Safety and Effectiveness of Subcutaneous Injection of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed DyslipidemiaCOMPLETEDINTERVENTIONALinclisiran
NCT06692764A Phase II Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants With Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-Density Lipoprotein CholesterolCOMPLETEDINTERVENTIONALPlacebo, AZD0780
NCT06640972A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of RDX-002 on Postprandial Triglycerides in Patients Discontinuing the Glucagon-like Peptide-1 (GLP-1) Agonists, Semaglutide, or Tirzepatide for the Treatment of ObesityCOMPLETEDINTERVENTIONALRDX-002, Placebo
NCT06567951Maternal Supraphysiological Hypercholesterolemia: Extra Virgin Olive Oil as a Nutritional Intervention During Pregnancy to Reduce the Impact of This Maternal ConditionNOT YET RECRUITINGINTERVENTIONALExtra Virgin Olive Oil (EVOO)
NCT06492291A Phase 3, Open-label Extension Study to Evaluate the Safety and Efficacy of MK-0616 in Adults With HypercholesterolemiaACTIVE NOT RECRUITINGINTERVENTIONALEnlicitide Decanoate
NCT06450366A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-0616 Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With HypercholesterolemiaCOMPLETEDINTERVENTIONALEnlicitide, Ezetimibe, Bempedoic Acid
NCT06293729A Clinical Study for the Safety and Efficacy of Intravenous Infusion of NGGT006 in Treatment of Refractory HypercholesterolemiaNOT YET RECRUITINGINTERVENTIONALNGGT006
NCT05587621"Intensive Lipid-Lowering Therapy Guided by a Cloud-based Software System (CLIMEDO GmbH) in Patients With ST-Elevation and Non-ST-Elevation Myocardial Infarctions" (Germany on Target)NOT YET RECRUITINGINTERVENTIONALstatins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran
NCT06140095Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid MetabolismUNKNOWNINTERVENTIONALEvolocumab
NCT05798442The Impact of Using a Smartphone Health Application in the Improvement of Cardiovascular Disease Risk Factors in the Omani Population; Prospective Randomized Clinical TrialNOT YET RECRUITINGINTERVENTIONALsmartphone health application (Opulse)
NCT06229548A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYH2053 in Subjects With Normal or Elevated Low-Density Lipoprotein CholesterolCOMPLETEDINTERVENTIONALSYH2053, Placebo
NCT05874141Comorbidities in Type 2 Diabetes Mellitus: An Observational Study in Kharga City, New Valley Governate, EgyptCOMPLETEDINTERVENTIONALHBA1C, Lipid profile, including total, LDL, and HDL cholesterol and Triglycerides, Urine analysis and urinary albumin-to-creatinine ratio
NCT06096909Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population (EMPACT): A Randomized Controlled TrialNOT YET RECRUITINGINTERVENTIONALTafolecimab, Cholesterol Absorption Inhibitor, Statin
NCT07295418A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Clinical Study to Evaluate the Safety and Efficacy of SAL003 Monotherapy in Participants With Hypercholesterolemia and Mixed DyslipidemiaCOMPLETEDINTERVENTIONALSAL003 140 mg, Placebo
NCT05758779Coronary CT Screening of Patients With Familial Hypercholesterolemia - The Prevalence of Subclinical Atherosclerosis in Familial Hypercholesterolemia in the Region of Southern DenmarkACTIVE NOT RECRUITINGINTERVENTIONALVisualization of coronary Imaging and oral description
NCT07442630A Multicenter Study to Evaluate Efficacy and SafetyACTIVE NOT RECRUITINGINTERVENTIONALPitavastatin 4mg, Ezetimibe 10 mg, Placebo (for Pitavastatin/Ezetimibe)
NCT05952856A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With HypercholesterolemiaCOMPLETEDINTERVENTIONALEnlicitide Decanoate, Placebo
NCT05952869A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Heterozygous Familial Hypercholesterolemia.COMPLETEDINTERVENTIONALEnlicitide Decanoate, Placebo
NCT05934292An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of MK-0616 in Participants With Varying Degrees of Renal ImpairmentCOMPLETEDINTERVENTIONALEnlicitide Decanoate
NCT05888103A 6 Month Randomized, Double-blind, Placebo-controlled Study Followed by a 6 Month Open- Label Extension to Assess the Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein CholesterolCOMPLETEDINTERVENTIONALInclisiran, Matching Placebo for Inclisiran
NCT07278830A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Safety and Efficacy of Recombinant Fully Human Anti-PCSK9 Monoclonal Antibody Injection (SAL003) Combined With Atorvastatin in Subjects With Hypercholesterolemia and Mixed DyslipidemiaCOMPLETEDINTERVENTIONALSAL003 140mg+Atorvastatin, SAL003 420mg+Atorvastatin, Placebo 140mg+Atorvastatin
NCT05839236COVID-19 Vaccination Detoxication in Low Density Lipoprotein CholesterolUNKNOWNINTERVENTIONALAtorvastatin Calcium Tablets
NCT05896969Phase 1, Single Multiple Dose Escalation Study in a Randomized, Double-blind, Placebo Controlled Design to Investigate Safety, Tolerability, PK and PD of SC Administered SNK-396 in Subjects With Elevated Low-Density Lipoprotein CholesterolCOMPLETEDINTERVENTIONALSNK-396 - SAD cohort, SNK-396 - MAD Cohort
NCT05613426Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (EVALUATE-STEMI Trial): a Prospective, Multicenter, Open-label, Adjudicator-blinded, Randomized Clinical TrialTERMINATEDINTERVENTIONALRosuvastatin 20 mg, Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]
NCT05763875A Double-blind, Randomized, Placebo- and Active-Comparator Controlled Study to Evaluate the Efficacy of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-Lowering Therapy (VictORION-Mono)COMPLETEDINTERVENTIONALInclisiran, Ezetimibe, Matching Placebo for Inclisiran
NCT05988099Comparison of the Effects of Standardized Chokeberry Extracts With Various Formulations on the Levels of Selected Markers Associated With Cardiovascular DiseaseCOMPLETEDINTERVENTIONALComplex product, Chokeberry extract in liposomal formulation, Chokeberry extract in traditional formulation
NCT05361421Effect of Intensive LDL-cholesterol Targeting for Elderly Patients With Cardiovascular Disease: I-OLD TrialACTIVE NOT RECRUITINGINTERVENTIONALIntensive targeting group, Conventional therapy group
NCT06435130The Impact of Chokeberry Bioproducts Consumption on Metabolic Parameters and the Antioxidant Potential of SerumCOMPLETEDINTERVENTIONALDietary intervention with chokeberry juices, Dietary intervention with chokeberry juices and fibers
NCT05261126A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With HypercholesterolemiaCOMPLETEDINTERVENTIONALEnclitide Chloride, Placebo

Genetic associations (0)

None linked.